Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Provided By GlobeNewswire
Last update: Mar 6, 2025
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Read more at globenewswire.com
